{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:24:35Z","timestamp":1780590275630,"version":"3.54.1"},"reference-count":44,"publisher":"Archives of Endocrinology and Metabolism","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,10]]},"DOI":"10.20945\/2359-3997000000190","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T13:26:31Z","timestamp":1578662791000},"page":"601-607","source":"Crossref","is-referenced-by-count":29,"title":["Perspectives on long-acting growth hormone therapy in children and adults"],"prefix":"10.20945","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8055-944X","authenticated-orcid":false,"given":"Rayhan A.","family":"Lal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0145-1917","authenticated-orcid":false,"given":"Andrew R.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"8","key":"key20200110141759_B1","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1210\/jcem-18-8-901","article-title":"Treatment of a pituitary dwarf with human growth hormone","volume":"18","author":"Raben","year":"1958","unstructured":"1. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab. 1958;18(8):901-3.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20200110141759_B2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1677\/joe.0.0820077","article-title":"Large-scale preparation of highly purified pyrogen-free human growth hormone for clinical use","volume":"82","author":"Jones","year":"1979","unstructured":"2. Jones RL, Benker G, Salacinski PR, Lloyd TJ, Lowry PJ. Large-scale preparation of highly purified pyrogen-free human growth hormone for clinical use. J Endocrinol. 1979;82(1):77-86.","journal-title":"J Endocrinol"},{"issue":"8","key":"key20200110141759_B3","first-page":"2298","article-title":"The prismatic case of Creutzfeldt-Jakob disease associated with pituitary growth hormone treatment","volume":"80","author":"Hintz","year":"1995","unstructured":"3. Hintz RL. The prismatic case of Creutzfeldt-Jakob disease associated with pituitary growth hormone treatment. J Clin Endocrinol Metab. 1995;80(8):2298-301.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"key20200110141759_B4","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1210\/jc.2005-0928","article-title":"Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency","volume":"90","author":"Hoffman","year":"2005","unstructured":"4. Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, et al.; Genentech Adult Growth Hormone Deficiency Study Group. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency. J Clin Endocrinol Metab. 2005;90(12):6431-40.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20200110141759_B5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12020-017-1492-1","article-title":"Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls","volume":"60","author":"Ramos-Lev\u00ed","year":"2018","unstructured":"5. Ramos-Lev\u00ed AM, Marazuela M. Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls. Endocrine. 2018;60(2):203-18.","journal-title":"Endocrine"},{"issue":"1","key":"key20200110141759_B6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4158\/EP13194.OR","article-title":"Adherence to growth hormone therapy: results of a multicenter study","volume":"20","author":"Ayd\u0131n","year":"2014","unstructured":"6. Ayd\u0131n BK, Aycan Z, S\u0131klar Z, Berberog5lu M, Ocal G, Cetinkaya S, et al. Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract. 2014;20(1):46-51.","journal-title":"Endocr Pract"},{"issue":"1","key":"key20200110141759_B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1515\/jpem-2017-0157","article-title":"Adherence to growth hormone therapy in children and its potential barriers","volume":"31","author":"Mohseni","year":"2018","unstructured":"7. Mohseni S, Heydari Z, Qorbani M, Radfar M. Adherence to growth hormone therapy in children and its potential barriers. J Pediatr Endocrinol Metab. 2018;31(1):13-20.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"key20200110141759_B8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00416","article-title":"Relevance of Adherence Monitoring in Adult Patients With Growth Hormone Deficiency Under Replacement Therapy: Preliminary Monocentric Data With EasypodTM Connect","volume":"10","author":"Mancini","year":"2019","unstructured":"8. Mancini A, Vergani E, Bruno C, Palladino A, Brunetti A. Relevance of Adherence Monitoring in Adult Patients With Growth Hormone Deficiency Under Replacement Therapy: Preliminary Monocentric Data With EasypodTM Connect. Front Endocrinol (Lausanne). 2019;10:416.","journal-title":"Front Endocrinol"},{"issue":"2","key":"key20200110141759_B9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4158\/EP.14.2.143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","volume":"14","author":"Rosenfeld","year":"2008","unstructured":"9. Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract. 2008;14(2):143-54.","journal-title":"Endocr Pract"},{"issue":"3","key":"key20200110141759_B10","first-page":"1222","article-title":"Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults","volume":"86","author":"Laursen","year":"2001","unstructured":"10. Laursen T, Gravholt CH, Heickendorff L, Drustrup J, Kappelgaard AM, J\u00f8rgensen JO, et al., Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab. 2001;86(3):1222-8.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"key20200110141759_B11","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1210\/jcem.86.10.7932","article-title":"A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency","volume":"86","author":"Reiter","year":"2001","unstructured":"11. Reiter EO, Attie KM, Moshang T Jr, Silverman BL, Kemp SF, Neuwirth RB, et al.; Genentech, Inc.-Alkermes, Inc. Collaborative Study Group. A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J Clin Endocrinol Metab. 2001;86(10):4700-6.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"key20200110141759_B12","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1210\/jc.2006-0514","article-title":"Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency","volume":"91","author":"Bidlingmaier","year":"2006","unstructured":"12. Bidlingmaier M, Kim J, Savoy C, Kim MJ, Ebrecht N, de la Motte S, et al. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J Clin Endocrinol Metab. 2006;91(8):2926-30.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20200110141759_B13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/EJE-08-0703","article-title":"Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency","volume":"160","author":"Peter","year":"2009","unstructured":"13. Peter F, Savoy C, Ji HJ, Juhasz M, Bidlingmaier M, Saenger P. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. Eur J Endocrinol. 2009;160(3):349-55.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"key20200110141759_B14","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1210\/jc.2010-2819","article-title":"Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency","volume":"96","author":"Biller","year":"2011","unstructured":"14. Biller BM, Ji HJ, Ahn H, Savoy C, Siepl EC, Popovic V, et al., Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. J Clin Endocrinol Metab. 2011;96(6):1718-26.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20200110141759_B15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11102-012-0422-8","article-title":"12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency","volume":"16","author":"Biller","year":"2013","unstructured":"15. Biller BM, Ji HJ, Ahn H, Savoy C, Siepl EC, Popovic V, et al. 12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency. Pituitary. 2013;16(3):311-8.","journal-title":"Pituitary"},{"issue":"1","key":"key20200110141759_B16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2265.2011.04146.x","article-title":"Effects on metabolic variables after 12-month treatment with a new once-a-week sustained-release recombinant growth hormone (GH: LB03002) in patients with GH deficiency","volume":"76","author":"Roemmler","year":"2012","unstructured":"16. Roemmler J, Gockel A, Otto B, Bidlingmaier M, Schopohl J. Effects on metabolic variables after 12-month treatment with a new once-a-week sustained-release recombinant growth hormone (GH: LB03002) in patients with GH deficiency. Clin Endocrinol (Oxf). 2012;76(1):88-95.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"key20200110141759_B17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2011-2234","article-title":"Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD)","volume":"97","author":"P\u00e9ter","year":"2012","unstructured":"17. P\u00e9ter F, Bidlingmaier M, Savoy C, Ji HJ, Saenger PH. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J Clin Endocrinol Metab. 2012;97(2):400-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20200110141759_B18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/EJE-13-0148","article-title":"Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency","volume":"169","author":"Hwang","year":"2013","unstructured":"18. Hwang JS, Lee HS, Chung WY, Han HS, Jin DK, Kim HS, et al. Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency. Eur J Endocrinol. 2013;169(2):179-85.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"key20200110141759_B19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/jc.2013-2502","article-title":"24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency","volume":"99","author":"Khadilkar","year":"2014","unstructured":"19. Khadilkar V, Radjuk KA, Bolshova E, Khadgawat R, El Kholy M, Desai M, et al., 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency. J Clin Endocrinol Metab. 2014;99(1):126-32.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20200110141759_B20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000489262","article-title":"Once-Weekly Administration of Sustained-Release Growth Hormone in Korean Prepubertal Children with Idiopathic Short Stature: A Randomized, Controlled Phase II Study","volume":"90","author":"Hwang","year":"2018","unstructured":"20. Hwang JS, Lee HS, Lee KH, Yoo HW, Lee DY, Suh BK, et al. Once-Weekly Administration of Sustained-Release Growth Hormone in Korean Prepubertal Children with Idiopathic Short Stature: A Randomized, Controlled Phase II Study. Horm Res Paediatr. 2018;90(1):54-63.","journal-title":"Horm Res Paediatr"},{"issue":"22","key":"key20200110141759_B21","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1073\/pnas.1100387108","article-title":"Optimized clinical performance of growth hormone with an expanded genetic code","volume":"108","author":"Cho","year":"2011","unstructured":"21. Cho H, Daniel T, Buechler YJ, Litzinger DC, Maio Z, Putnam AM, et al., Optimized clinical performance of growth hormone with an expanded genetic code. Proc Natl Acad Sci U S A. 2011;108(22):9060-5.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"key20200110141759_B22","first-page":"13","article-title":"Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children","author":"Hou","year":"2015","unstructured":"22. Hou L, Chen ZH, Liu D, Cheng YG, Luo XP. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children. Drug Des Devel Ther. 2015;10:13-21.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"key20200110141759_B23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-16-0905","article-title":"Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies","volume":"177","author":"Luo","year":"2017","unstructured":"23. Luo X, Hou L, Liang L, Dong G, Shen S, Zhao Z, et al. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol. 2017;177(2):195-205.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"key20200110141759_B24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jcpt.12732","article-title":"A long-acting pegylated recombinant human growth hormone (Jintrolong\u00ae) in healthy adult subjects: Two single-dose trials evaluating safety, tolerability and pharmacokinetics","volume":"43","author":"Guan","year":"2018","unstructured":"24. Guan Y, He F, Wu J, Zhao L, Wang X, Huang L, et al., A long-acting pegylated recombinant human growth hormone (Jintrolong\u00ae) in healthy adult subjects: Two single-dose trials evaluating safety, tolerability and pharmacokinetics. J Clin Pharm Ther. 2018;43(5):640-6.","journal-title":"J Clin Pharm Ther"},{"key":"key20200110141759_B25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ghir.2017.12.002","article-title":"A first-in-man phase 1 trial for long-acting TransCon Growth Hormone","volume":"39","author":"Gilfoyle","year":"2018","unstructured":"25. Gilfoyle D, Mortensen E, Christoffersen ED, Leff JA, Beckert M. A first-in-man phase 1 trial for long-acting TransCon Growth Hormone. Growth Horm IGF Res. 2018;39:34-9.","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"key20200110141759_B26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1530\/EC-17-0007","article-title":"A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency","volume":"6","author":"H\u00f6ybye","year":"2017","unstructured":"26. H\u00f6ybye C, Pfeiffer AF, Ferone D, Christiansen JS, Gilfoyle D, Christoffersen ED, et al. A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency. Endocr Connect. 2017;6(3):129-38.","journal-title":"Endocr Connect"},{"issue":"5","key":"key20200110141759_B27","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1210\/jc.2016-3776","article-title":"A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency","volume":"102","author":"Chatelain","year":"2017","unstructured":"27. Chatelain P, Malievskiy O, Radziuk K, Senatorova G, Abdou MO, Vlachopapadopoulou E, et al., A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency. J Clin Endocrinol Metab. 2017;102(5):1673-82.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supplement_1","key":"key20200110141759_B28","article-title":"OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial","volume":"3","author":"Thornton","year":"2019","unstructured":"28. Thornton P, Hofman P, Maniatis A, Aghajanova E, Chertok E, Korpal-Szczyrska M, et al. OR17-4 Transcon Growth Hormone In The Treatment Of Pediatric Growth Hormone Deficiency: Results Of The Phase 3 Height Trial. J Clin Endocrinol Metab. 2019. 3(Supplement_1).","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200110141759_B29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ghir.2017.05.006","article-title":"Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone","volume":"35","author":"Thygesen","year":"2017","unstructured":"29. Thygesen P, Andersen HS, Behrens C, Fels JJ, N\u00f8rskov-Lauritsen L, Rischel C, et al., Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone. Growth Horm IGF Res. 2017;35:8-16.","journal-title":"Growth Horm IGF Res"},{"issue":"10","key":"key20200110141759_B30","doi-asserted-by":"crossref","first-page":"E1819","DOI":"10.1210\/jc.2014-1702","article-title":"A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile","volume":"99","author":"Rasmussen","year":"2014","unstructured":"30. Rasmussen MH, Olsen MW, Alifrangis L, Klim S, Suntum M. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile. J Clin Endocrinol Metab. 2014;99(10):E1819-29.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20200110141759_B31","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1210\/jc.2015-1991","article-title":"Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency","volume":"101","author":"Rasmussen","year":"2016","unstructured":"31. Rasmussen MH, Janukonyt\u00e9 J, Klose M, Marina D, Tanvig M, Nielsen LF, et al., Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency. J Clin Endocrinol Metab. 2016;101(3):988-98.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20200110141759_B32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/cen.13409","article-title":"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial","volume":"87","author":"Battelino","year":"2017","unstructured":"32. Battelino T, Rasmussen MH, De Schepper J, Zuckerman-Levin N, Gucev Z, S\u00e4vendahl L, et al. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial. Clin Endocrinol (Oxf). 2017;87(4):350-8.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"key20200110141759_B33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-17-1073","article-title":"Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial","volume":"178","author":"Johannsson","year":"2018","unstructured":"33. Johannsson G, Feldt-Rasmussen U, H\u00e5konsson IH, Biering H, Rodien P, Tahara S, et al. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur J Endocrinol. 2018;178(5):491-9.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"key20200110141759_B34","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1039\/c3nr00474k","article-title":"Controlled release of human growth hormone fused with a human hybrid Fc fragment through a nanoporous polymer membrane","volume":"5","author":"Kim","year":"2013","unstructured":"34. Kim ES, Jang DS, Yang SY, Lee MN, Jin KS, Cha HJ, et al. Controlled release of human growth hormone fused with a human hybrid Fc fragment through a nanoporous polymer membrane. Nanoscale. 2013;5(10):4262-9.","journal-title":"Nanoscale"},{"issue":"3","key":"key20200110141759_B35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1530\/EJE-18-0185","article-title":"Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults","volume":"179","author":"Ku","year":"2018","unstructured":"35. Ku CR, Brue T, Schilbach K, Ignatenko S, Magony S, Chung YS, et al., Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults. Eur J Endocrinol. 2018;179(3):169-79.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"key20200110141759_B36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/acs.molpharmaceut.5b00868","article-title":"In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone","volume":"13","author":"Hershkovitz","year":"2016","unstructured":"36. Hershkovitz O, Bar-Ilan A, Guy R, Felikman Y, Moschcovich L, Hwa V, et al., In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone. Mol Pharm. 2016;13(2):631-9.","journal-title":"Mol Pharm"},{"issue":"3","key":"key20200110141759_B37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1530\/EJE-16-0748","article-title":"MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults","volume":"176","author":"Strasburger","year":"2017","unstructured":"37. Strasburger CJ, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L, et al., MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults. Eur J Endocrinol. 2017;176(3):283-94.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"key20200110141759_B38","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1210\/jc.2016-3547","article-title":"Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children","volume":"102","author":"Zelinska","year":"2017","unstructured":"38. Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L, et al. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children. J Clin Endocrinol Metab. 2017;102(5):1578-87.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20200110141759_B39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000470842","article-title":"Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children","volume":"87","author":"Fisher","year":"2017","unstructured":"39. Fisher DM, Rosenfeld RG, Jaron-Mendelson M, Amitzi L, Koren R, Hart G, et al. Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children. Horm Res Paediatr. 2017;87(5):324-32.","journal-title":"Horm Res Paediatr"},{"issue":"5","key":"key20200110141759_B40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1530\/EJE-15-0554","article-title":"Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency","volume":"173","author":"Cohen-Barak","year":"2015","unstructured":"40. Cohen-Barak O, Sakov A, Rasamoelisolo M, Bassan M, Brown K, Mendzelevski B, et al. Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency. Eur J Endocrinol. 2015;173(5):541-51.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"key20200110141759_B41","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1210\/jc.2015-3279","article-title":"A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency","volume":"101","author":"Moore","year":"2016","unstructured":"41. Moore WV, Nguyen HJ, Kletter GB, Miller BS, Rogers D, Ng D, et al. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency. J Clin Endocrinol Metab. 2016;101(3):1091-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20200110141759_B42","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/EJE-16-0111","article-title":"Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations","volume":"174","author":"Christiansen","year":"2016","unstructured":"42. Christiansen JS1, Backeljauw PF2, Bidlingmaier M3, Biller BM4, Boguszewski MC5, Casanueva FF, et al. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016;174(6):C1-8.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"key20200110141759_B43","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-15-0873","article-title":"GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults","volume":"174","author":"Allen","year":"2016","unstructured":"43. Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174(2):P1-9.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"key20200110141759_B44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1210\/jc.2011-2294","article-title":"Long-term surveillance of growth hormone therapy","volume":"97","author":"Rosenfeld","year":"2012","unstructured":"44. Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, Hoffman AR, et al. Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab. 2012;97(1):68-72.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T14:18:35Z","timestamp":1578665915000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S2359-39972019000900601&lng=en&nrm=iso"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,1,10]]}},"alternative-id":["10.20945\/2359-3997000000190"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000190","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}